Mar. 10, 2020

Teijin Pharma to Supply Ciclesonide for COVID-19 Clinical Research

Teijin Pharma Limited

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, announced today that it received a request on March 9 to supply ciclesonide, an inhaled corticosteroid for asthma, for study as a possible therapeutic agent for COVID-19 by the Tuberculosis and Infectious Diseases Control Division of the Japanese Ministry of Health, Labor and Welfare's Bureau of Health Service.

Teijin Pharma manufactures and sells ciclesonide in Japan under license from a foreign entity. The company will respond to the Ministry’s request after assuring it has a stable supply of ciclesonide for bronchial asthma patients now using the drug.

Ciclesonide is currently indicated for bronchial asthma but not COVID-19. It is contraindicated for patients with infectious diseases or deep mycosis without effective antibacterial agents.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the areas of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has over 170 companies and around 20,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY888.6 billion (USD 8.1 billion) and total assets of JPY 1,020.7 billion (USD 9.3 billion) in the fiscal year ending March 31, 2019. Please visit

Press Contact

Corporate Communications
Teijin Limited